Company / SG&A Expense
Fulcrum Therapeutics, Inc. SG&A Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$28.7M
FY2025
5-year range
$28.7M / $41.7M
FY2021-FY2025
Trend
-21.4%
vs FY2024
Sector context
#189 of 213
Health Care
What the data says
Fulcrum Therapeutics, Inc.'s sg&a expense of $29M is lower than 89% of companies in the Health Care sector (FY2025). SG&A Expense has declined for 3 consecutive years, from $42M in FY2022 to $29M in FY2025.
Based on SEC 10-K filings.
$29M in FY2025 with a 5-year CAGR of +6.0%.
Improved from $42M to $29M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -11.7%
- 5-Year CAGR
- +6.0%
- 10-Year CAGR
- -
Sector benchmark
Top 11% in Health CareTop 11% of 213This company $28.7M Sector average $722.3M
▼
-96.0% below sector average
Key checks
Key Insights
- Fulcrum Therapeutics, Inc.'s sg&a expense has declined for 3 consecutive years.
- 5-year CAGR of +6.0%, indicating consistent growth.
- In FY2025, sg&a expense decreased 21.4% year-over-year.
- Ranks #189 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 8.44 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $28.7M | -21.4% |
| FY2024 | $36.4M | -12.5% |
| FY2023 | $41.7M | -0.1% |
| FY2022 | $41.7M | +36.6% |
| FY2021 | $30.5M | +42.7% |
| FY2020 | $21.4M | +62.7% |
| FY2019 | $13.1M | +58.1% |
| FY2018 | $8.3M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026